Clinical Trial Update: Study of Ranibizumab Administered in Conjunction With Photodynamic Therapy With Verteporfin in Patients With Subfoveal Choroidal Neovascularization and Age-Related Macular Degeneration [Phase 2]

View source ↗

Summary

Phase 2 study evaluating ranibizumab in combination with verteporfin photodynamic therapy for subfoveal choroidal neovascularization in age-related macular dege…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration

Drugs mentioned

• Lucentis (ranibizumab)
• Visudyne (verteporfin)

Snippet

Sponsor: Novartis | Conditions: Age-Related Macular Degeneration (ARMD) | Phase 2 | Status: COMPLETED